Tubingen, Germany
HepaRegeniX GmbH is a promising clinical-stage biotechnology company founded in 2017 in Germany. With the slogan "Unlocking liver regeneration - delivering recovery," the company is making significant strides in developing novel therapies aimed at treating both acute and chronic liver diseases.
The company operates within several dynamic sectors, including Biotechnology, Health Care, Health and Wellness, and Life Sciences. This strategic positioning offers a strong foundation for growth, particularly as global demand for innovative healthcare solutions is on the rise.
Most recently, HepaRegeniX GmbH attracted a $21.50M Late VC investment on 01 June 2025. Notable investors include Novo Holdings, Wellington Partners, and Vesalius Biocapital. These investments underscore confidence in the company’s potential to transform liver disease treatment and offer compelling opportunities for both medical advancement and financial returns.
